Compounds activating the glmS riboswitch

Cyclohexane compounds and their use as antibiotics.

Invention – The present invention relates to cyclohexane compounds for the treatment of a bacterial infection, particularly for use as an antibiotic. Since the discovery of antibiotic substances and their use against microbes, bacteria have evolved to defend themselves by acquiring resistances. Especially in hospitals where bacteria are exposed to a wide array of antibacterial substances, multiresistant strains (e.g. MRSA) arose. This is why it is not only necessary to have an ongoing search for new antibiotic substances, but to also find and use new antibacterial targets enforcing new mechanisms of action. Riboswitches have appeared as one new promising target for antibacterial defence. Riboswitches are mostly found in the 5'-untranslated region of bacterial mRNA and regulate 2-4% of all bacterial genes. In the past it has been shown that metabolite analogues can be employed to trigger riboswitch function thereby modulating its regulatory character. Thus, it would be desirable to provide compounds that also target the glmS riboswitch and exhibit antimicrobial activity. The problem is solved by a compound according to general formula (I) as shown in the figure above. Beneficially, the compounds according to the invention can be useful as an antibacterial substance in the treatment of bacterial infection. The present invention therefore provides a novel approach to the treatment of bacterial infection.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Recovering phosphorus from sewage sludge ash

Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…

Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids

EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…

After 25 years, researchers uncover genetic cause of rare neurological disease

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…

Partners & Sponsors